Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2016-11-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于变更中源协和生命医学奖设立主体暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding a change in the establishment entity of a life science award and related related-party transactions. It details the background, parties involved, the award's purpose, and the board's approval process. There is no financial data, no quarterly or annual financial results, no audit information, no earnings release, no management discussion of financial results, no merger or acquisition activity, no voting results, no dividend information, and no regulatory certification. The document is a formal announcement of a corporate governance and related-party transaction matter. It is not a report or financial statement but an announcement of a corporate event. The document length is 3673 characters, which is relatively short and consistent with an announcement. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2016-11-28 Chinese
关于子公司参与设立天津旷博协和生物技术有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about a subsidiary's investment in establishing a new joint venture company. It includes information about the investment amount, shareholder details, board resolutions, business scope, risk analysis, and the impact on the listed company. There are no financial statements or quarterly/yearly financial results presented. The document is not a report itself but an announcement of a corporate action related to capital investment and business expansion. This fits the category of Capital/Financing Update (CAP), as it updates on company fundraising and capital structure changes through the establishment of a new company via investment.
2016-10-31 Chinese
2016年第三季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2016 年第三季度报告" which translates to "2016 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss items, cash flow items, and shareholder information for the third quarter of 2016. The report is unaudited as stated in the text. The content includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, specifically a quarter. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q3 2016
2016-10-27 Chinese
第八届董事会第五十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 中源协和细胞基因工程股份有限公司, dated October 28, 2016. It reports the approval of the company's 2016 third quarter report and an internal control manual revision. The document is short (586 characters) and states that the full 2016 third quarter report is available on the Shanghai Stock Exchange website, indicating this document is not the report itself but an announcement of the board's approval of the report. Therefore, it is a Board/Management Information (MANG) filing, as it relates to board meeting resolutions and decisions rather than the full quarterly report or financial data itself.
2016-10-27 Chinese
关于子公司完成工商注册登记的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of business registration for a newly established subsidiary. It includes details such as company name, type, address, legal representative, registered capital, establishment date, and business scope. There is no financial data, no mention of financial results, no regulatory certifications, or voting results. The document is an official announcement about a corporate event (subsidiary registration) rather than a report or financial filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-10-19 Chinese
关于设立中源协和生命医学奖的进展暨与中国科学院大学签署合作协议书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the establishment of a new life sciences award and a cooperation agreement with a university. It details the award categories, committee structure, and the company's strategic intentions. There are no financial statements, audit information, or regulatory filings related to financial results. The document is an announcement of a corporate initiative and cooperation agreement, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about a new award and partnership, which is best classified under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other specific categories.
2016-09-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.